Lichuang Men

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Qian Jiang, Zongru Li, Ya‐Zhen Qin et al. · Journal of Hematology & Oncology · 2022 · 99 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

Sikander Ailawadhi, Zi Chen, Bo Huang et al. · Clinical Cancer Research · 2023 · 38 citations · Full text

Medicine, Oncology, Pharmacology +17

First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors

Nehal J. Lakhani, Drew Rasco, Hengbang Wang et al. · Clinical Cancer Research · 2023 · 24 citations

Medicine, Oncology, Pharmacology +16

Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.

Haibo Qiu, Zhiwei Zhou, Ye Zhou et al. · Journal of Clinical Oncology · 2024 · 13 citations

Medicine, Oncology, Pharmacology +13